Author

Karly Alex Cody

University of Wisconsin–MadisonORCID 0000-0001-5996-2560Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Research Focus:differential expression· 2 Assay:imaging· 2 Assay:proteomics· 1

Frequent Co-Authors

Charles K. Stone· 2 shared Sterling C. JohnsoniD· 2 shared Tobey J. BetthauseriD· 2 shared Todd E. BarnhartiD· 2 shared Adam L. BoxeriD· 1 shared Adam M. StaffaroniiD· 1 shared Ahmed AbdelhakiD· 1 shared Alexander K. ConverseiD· 1 shared

Activity by Year

2018-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Charles K. Stone

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NeurosciencebioRxivPreprintOct 8, 2026

Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration

Rowan Saloner, Louisa Cornelis, Joshua D. Downer…·Adam L. Boxer

The paper identifies potential diagnostic biomarkers for frontotemporal lobar degeneration subtypes using cerebrospinal fluid proteomics.

DOI 10.64898/2026.09.29.755483

humanproteomics

𝕏 PostBluesky

NeuroscienceAlzheimer s & Dementia Diagnosis Assessment & Disease MonitoringPeer-reviewedJan 1, 2020

Amyloid duration is associated with preclinical cognitive decline and tau PET

Rebecca L. Koscik, Tobey J. Betthauser, Erin McMullen Jonaitis…·Sterling C. Johnson

This study uses longitudinal amyloid PET data to estimate amyloid chronicity and finds it is linked to cognitive decline and tau burden in preclinical Alzheimer's disease.

104 citationstop 1%

𝕏 PostBluesky

NeuroscienceJournal of Nuclear MedicinePeer-reviewedMay 18, 2018

In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer’s disease dementia to young controls

Tobey J. Betthauser, Karly Alex Cody, Matthew D. Zammit…·Bradley Christian

This paper evaluates the in vivo kinetics and quantification of the tau PET radioligand [18F]MK-6240 in humans across Alzheimer’s disease stages and controls.

258 citationstop 1%

𝕏 PostBluesky